Growth Prospects of the Myocardial Infarction - Pipeline Review, H2 2016
Myocardial Infarction - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Myocardial Infarction pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.
To access full report with TOC, please visit Myocardial Infarction - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amarantus Bioscience Holdings, Inc. Asterias Biotherapeutics, Inc. AstraZeneca Plc Athersys, Inc. Bayer AG Bharat Biotech International Limited BioCardia, Inc. Biscayne Pharmaceuticals, Inc. Capricor Therapeutics, Inc. CellProthera Celyad SA Chrysalis BioTherapeutics, Inc. Compugen Ltd. CSL Limited Cynata Therapeutics Limited Diffusion Pharmaceuticals Inc. FibroGen, Inc. Hemostemix Ltd Hope Pharmaceuticals, Inc. Human Stem Cells Institute HUYA Bioscience International, LLC Inotrem S.A. Juventas Therapeutics, Inc. Laboratoires Pierre Fabre SA Lee's Pharmaceutical Holdings Limited LegoChem Biosciences, Inc LG Life Science LTD. Medestea Research & Production S.p.A. Mesoblast Limited miRagen Therapeutics, Inc. Moderna Therapeutics Inc Navya Biologicals Pvt Ltd NeuroVive Pharmaceutical AB New World Laboratories, Inc. Novartis AG NuvOx Pharma LLC Omeros Corporation Opsona Therapeutics Limited Otsuka Holdings Co., Ltd. Pfizer Inc. Pharmathen Pharmaceuticals S.A. Primary Peptides, Inc. Quantum Genomics SA Quark Pharmaceuticals, Inc. Recardio GmbH RegeneRx Biopharmaceuticals, Inc. Serodus ASA Silver Creek Pharmaceuticals, Inc. Stealth BioTherapeutics Inc. Stemedica Cell Technologies, Inc. TaiGen Biotechnology Co., Ltd. Targazyme, Inc. The International Biotechnology Center (IBC) Generium TiGenix NV Vicore Pharma AB XBiotech Inc Yuyu Pharma, Inc. Zydus Cadila Healthcare Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 22:39
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home